Table I.

Patient baseline characteristics of 14 TSC/LAM patients prescribed oral sirolimus.

Mean age (range)	37 years (25–52)
Sirolimus median daily dose (range)	2 mg (1–7)
Angiofibromas	9/11*
Prior ablative therapy	4/9
Shagreen patch	7/11*
Ungual fibroma	5/11*

^*Eleven patients had pre-treatment (baseline) skin photographs available for analysis of cutaneous responses to oral sirolimus. Of the three patients without baseline photographs, 3/3 had angiofibromas (1 with prior ablative therapy), 1 had a shagreen patch and 1 had ungual fibromas.